A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer

Published:2011-05 Issue:3 Volume:12 Page:187-191
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Spigel David R.,Greco F. Anthony,Burris Howard A.,Shipley Dianna L.,Clark Bobby L.,Whorf Robert C.,Arrowsmith Edward R.,Hainsworth John D.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;von Pawel;J Clin Oncol,1999

2. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer;Bhoola;Gynecol Oncol,2004

3. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study;Frasci;Ann Oncol,1999

4. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer;Gelderblom;Br J Cancer,2001

5. A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients;Homesley;Gynecol Oncol,2002

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Established anticancer agents from plants;Advances in Botanical Research;2024

2. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion;Advances in Therapy;2021-09-26

3. Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy;Process Biochemistry;2021-05

4. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin;Molecular Cancer Therapeutics;2019-03-14

5. Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer;The Oncologist;2017-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3